Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Eur Urol. 2021 Mar 27;80(1):71–81. doi: 10.1016/j.eururo.2021.03.005

Table 2 –

Published clinical trials in prostate cancer with drugs targeting epigenetic factors

S. no. Drug Target Combination Phase Indication Trial identifier PubMed ID Year published
1 LBH589 HDAC 2 Metastatic castration-resistant prostate cancer NCT00667862 23820963 2013
2 Valproic acid HDAC Bevacizumab 1 Metastatic castration-resistant prostate cancer NCT00530907 24435060 2014
3 Azacitidine DNMT Docetaxel/prednisone 1, 2 Metastatic castration-resistant prostate cancer NCT00503984 25178642 2015
4 SB939 HDAC 2 Metastatic castration-resistant prostate cancer NCT01075308 25983041 2015
5 MK-8628 BET 1b Metastatic castration- resistait prostate cancer NCT02259114 29733771 2018
6 LBH589 HDAC Bicalutamide 2 Metastatic castration-resistant prostate cancer NCT00878436 30224345 2019
7 ABBV-075 BET 1 Metastatic castration-resistant prostate cancer NCT02391480 31420359 2019
8 ZEN003694 BET Enzalutamide 1, 2 Metastatic castration-resistant prostate cancer NCT02711956 32694156 2020

BET = bromodomain and extraterminal; HDAC = histone deacetylase.